Researchers at Johns Hopkins University School of Medicine have generated hundreds of three-dimensional brain models from cells taken from people with and without Alzheimer’s disease. These serotonergic hindbrain organoids, grown from induced pluripotent stem cells reprogrammed from blood samples, reproduce several molecular features of the illness, including shifts in proteins tied to brain cell communication, inflammation and established disease pathways.
The work stands out for its scale. With material from roughly 30 stem cell lines, the study represents one of the larger organoid cohorts reported so far. Its results, published in Alzheimer’s & Dementia, offer a patient-specific platform that captures biological variation often lost in simpler models.
When the organoids were treated with escitalopram oxalate, an SSRI frequently prescribed for the anxiety, depression and agitation that accompany Alzheimer’s, the responses varied sharply. Some patient-derived models showed clear increases in proteins involved in serotonin signalling and neuronal communication. Others displayed little or no change. This heterogeneity echoes the inconsistent clinical outcomes seen in patients taking the drug.
Proteins in secreted vesicles offer new clues
The team also examined extracellular vesicles released by the organoids. These tiny packages contained proteins that differed between those from Alzheimer’s patients and healthy controls. Levels of RAB3A, NSF and ATCAY were reduced in the patient-derived material. Proteomic analysis of both the organoids and their vesicles identified potential biomarkers that could aid early detection, disease staging and prediction of treatment response.
Such findings matter because Alzheimer’s remains stubbornly individual. Two people with similar symptoms can differ markedly in how their brains react to the same medicine. Models that respect this reality move the field closer to approaches tailored to each patient rather than one-size-fits-all assumptions.
The research rests on rigorous, peer-reviewed methods and draws on consented samples from the Johns Hopkins Alzheimer’s Disease Research Center. It prioritises observable molecular differences over speculative claims, aligning with a tradition of careful laboratory validation. Independent voices in the field have long called for larger, more diverse organoid studies precisely because smaller experiments risk overstating uniformity where variation reigns.
